| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Ebolavirus | 6 | 2018 | 834 | 1.87 | Why? |
| Hemorrhagic Fever, Ebola | 9 | 2018 | 1475 | 1.85 | Why? |
| Survivors | 6 | 2018 | 2619 | 0.76 | Why? |
| Uveitis, Posterior | 1 | 2017 | 10 | 0.71 | Why? |
| Sierra Leone | 5 | 2018 | 267 | 0.59 | Why? |
| Pneumothorax | 1 | 2021 | 758 | 0.49 | Why? |
| Retinal Diseases | 1 | 2017 | 441 | 0.46 | Why? |
| Eye Infections, Viral | 1 | 2017 | 517 | 0.39 | Why? |
| United Kingdom | 24 | 2021 | 18046 | 0.38 | Why? |
| Blood Donors | 2 | 2020 | 2956 | 0.35 | Why? |
| Observational Studies as Topic | 2 | 2021 | 1887 | 0.26 | Why? |
| World Health Organization | 5 | 2021 | 4213 | 0.24 | Why? |
| Hospitalization | 14 | 2021 | 54280 | 0.24 | Why? |
| Hemagglutination Tests | 1 | 2021 | 124 | 0.21 | Why? |
| Clinical Protocols | 5 | 2021 | 2734 | 0.19 | Why? |
| Genetic Fitness | 1 | 2021 | 339 | 0.18 | Why? |
| Theophylline | 1 | 2018 | 39 | 0.18 | Why? |
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2018 | 72 | 0.18 | Why? |
| Liberia | 1 | 2018 | 108 | 0.18 | Why? |
| Ophthalmoscopes | 1 | 2017 | 6 | 0.18 | Why? |
| Plasma | 2 | 2020 | 1809 | 0.17 | Why? |
| Bed Occupancy | 1 | 2021 | 476 | 0.17 | Why? |
| Albuterol | 1 | 2017 | 105 | 0.17 | Why? |
| Mobility Limitation | 1 | 2018 | 153 | 0.16 | Why? |
| Clinical Deterioration | 1 | 2021 | 473 | 0.16 | Why? |
| Asthma | 3 | 2021 | 4383 | 0.15 | Why? |
| Convalescence | 2 | 2018 | 2829 | 0.15 | Why? |
| HIV Infections | 1 | 2021 | 11620 | 0.15 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.15 | Why? |
| Hospital Mortality | 8 | 2021 | 22087 | 0.14 | Why? |
| HIV | 1 | 2021 | 1116 | 0.14 | Why? |
| Influenza A Virus, H1N1 Subtype | 3 | 2021 | 2984 | 0.14 | Why? |
| Uveitis | 1 | 2017 | 233 | 0.13 | Why? |
| Vision Disorders | 1 | 2018 | 260 | 0.13 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.13 | Why? |
| Humans | 51 | 2022 | 930598 | 0.13 | Why? |
| Public Health Administration | 1 | 2021 | 846 | 0.12 | Why? |
| Population Surveillance | 2 | 2020 | 4967 | 0.12 | Why? |
| Intellectual Disability | 1 | 2018 | 391 | 0.11 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.11 | Why? |
| Visual Acuity | 1 | 2017 | 790 | 0.11 | Why? |
| Cohort Studies | 8 | 2021 | 36005 | 0.10 | Why? |
| Blood Component Transfusion | 1 | 2016 | 740 | 0.10 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.10 | Why? |
| Minority Groups | 1 | 2021 | 1631 | 0.10 | Why? |
| Coronavirus Infections | 13 | 2020 | 253789 | 0.10 | Why? |
| History, 21st Century | 1 | 2017 | 1849 | 0.10 | Why? |
| Influenza, Human | 4 | 2021 | 10779 | 0.10 | Why? |
| Lung Diseases, Interstitial | 1 | 2020 | 1476 | 0.10 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.10 | Why? |
| Carrier State | 1 | 2021 | 2100 | 0.10 | Why? |
| Immunologic Memory | 1 | 2020 | 3362 | 0.09 | Why? |
| Seroepidemiologic Studies | 3 | 2020 | 10017 | 0.09 | Why? |
| Sensitivity and Specificity | 5 | 2021 | 22971 | 0.09 | Why? |
| Blood Coagulation Disorders | 1 | 2021 | 2040 | 0.09 | Why? |
| Hospitals | 3 | 2021 | 11793 | 0.08 | Why? |
| Critical Care | 5 | 2021 | 14081 | 0.08 | Why? |
| Russia | 2 | 2021 | 989 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Disabled Persons | 1 | 2018 | 1152 | 0.08 | Why? |
| Female | 25 | 2022 | 380317 | 0.08 | Why? |
| Guinea | 2 | 2017 | 228 | 0.08 | Why? |
| Comorbidity | 5 | 2021 | 34796 | 0.08 | Why? |
| Family Characteristics | 1 | 2017 | 2551 | 0.08 | Why? |
| Male | 23 | 2021 | 367725 | 0.08 | Why? |
| Prospective Studies | 8 | 2022 | 43301 | 0.08 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.08 | Why? |
| Pneumonia, Viral | 12 | 2020 | 243684 | 0.07 | Why? |
| Betacoronavirus | 10 | 2020 | 204454 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.07 | Why? |
| Adult | 14 | 2021 | 244371 | 0.07 | Why? |
| England | 3 | 2021 | 5116 | 0.07 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.07 | Why? |
| Pandemics | 15 | 2021 | 389249 | 0.06 | Why? |
| Respiration, Artificial | 4 | 2021 | 22116 | 0.06 | Why? |
| Obesity | 2 | 2021 | 7388 | 0.06 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.06 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3832 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.06 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.06 | Why? |
| Models, Statistical | 1 | 2020 | 5312 | 0.06 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.06 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.06 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.06 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.06 | Why? |
| Disease Outbreaks | 4 | 2018 | 27595 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.06 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.06 | Why? |
| Infant | 6 | 2020 | 30274 | 0.06 | Why? |
| Child | 9 | 2022 | 70012 | 0.06 | Why? |
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2020 | 73 | 0.06 | Why? |
| Chromosomes, Human, Pair 19 | 1 | 2020 | 77 | 0.06 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.05 | Why? |
| Chromosomes, Human, Pair 12 | 1 | 2020 | 84 | 0.05 | Why? |
| Chromosomes, Human, Pair 21 | 1 | 2020 | 90 | 0.05 | Why? |
| TYK2 Kinase | 1 | 2020 | 116 | 0.05 | Why? |
| Receptors, CCR2 | 1 | 2020 | 103 | 0.05 | Why? |
| Health Policy | 1 | 2021 | 6242 | 0.05 | Why? |
| Agglutination Tests | 1 | 2021 | 124 | 0.05 | Why? |
| Child, Preschool | 6 | 2020 | 36283 | 0.05 | Why? |
| Aged | 13 | 2022 | 215776 | 0.05 | Why? |
| Northern Ireland | 1 | 2020 | 228 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.05 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.05 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 7868 | 0.05 | Why? |
| 2',5'-Oligoadenylate Synthetase | 1 | 2020 | 205 | 0.05 | Why? |
| Multigene Family | 1 | 2020 | 377 | 0.05 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.05 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.05 | Why? |
| Tomography, X-Ray Computed | 3 | 2020 | 25144 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Research Design | 1 | 2016 | 5830 | 0.05 | Why? |
| Sequence Analysis | 1 | 2020 | 496 | 0.05 | Why? |
| Adolescent | 8 | 2022 | 86841 | 0.05 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.05 | Why? |
| Histones | 1 | 2021 | 371 | 0.05 | Why? |
| ROC Curve | 2 | 2021 | 6024 | 0.05 | Why? |
| DNA, Complementary | 1 | 2020 | 568 | 0.05 | Why? |
| Receptor, Interferon alpha-beta | 1 | 2020 | 610 | 0.05 | Why? |
| Child, Hospitalized | 1 | 2022 | 556 | 0.04 | Why? |
| Ghana | 1 | 2021 | 763 | 0.04 | Why? |
| Wales | 1 | 2020 | 758 | 0.04 | Why? |
| Asymptomatic Infections | 1 | 2017 | 7218 | 0.04 | Why? |
| Geography, Medical | 1 | 2020 | 537 | 0.04 | Why? |
| Inhibitory Concentration 50 | 1 | 2020 | 907 | 0.04 | Why? |
| Gas Chromatography-Mass Spectrometry | 1 | 2017 | 187 | 0.04 | Why? |
| Norway | 1 | 2021 | 1004 | 0.04 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.04 | Why? |
| Scotland | 1 | 2020 | 1119 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2016 | 7330 | 0.04 | Why? |
| Colombia | 1 | 2021 | 1241 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.04 | Why? |
| Immunodominant Epitopes | 1 | 2020 | 813 | 0.04 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.04 | Why? |
| Databases, Factual | 2 | 2020 | 6248 | 0.04 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.04 | Why? |
| Models, Immunological | 1 | 2020 | 727 | 0.04 | Why? |
| Acute Disease | 2 | 2018 | 6029 | 0.04 | Why? |
| Molecular Epidemiology | 1 | 2020 | 1638 | 0.03 | Why? |
| Risk Factors | 5 | 2022 | 71621 | 0.03 | Why? |
| Intention to Treat Analysis | 1 | 2016 | 673 | 0.03 | Why? |
| Containment of Biohazards | 1 | 2020 | 762 | 0.03 | Why? |
| Infant, Newborn | 3 | 2020 | 23105 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.03 | Why? |
| Program Development | 1 | 2020 | 1089 | 0.03 | Why? |
| Blood Specimen Collection | 1 | 2017 | 387 | 0.03 | Why? |
| Virulence | 1 | 2021 | 2172 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2020 | 1648 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2021 | 1061 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2022 | 17020 | 0.03 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.03 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 1439 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Glycoproteins | 1 | 2017 | 615 | 0.03 | Why? |
| Diagnostic Imaging | 1 | 2020 | 1044 | 0.03 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.03 | Why? |
| Administration, Inhalation | 1 | 2017 | 1647 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Urban Population | 1 | 2020 | 2000 | 0.03 | Why? |
| Public Opinion | 1 | 2020 | 1165 | 0.03 | Why? |
| DNA, Viral | 1 | 2020 | 2521 | 0.03 | Why? |
| Pilot Projects | 1 | 2021 | 5182 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2020 | 2262 | 0.02 | Why? |
| Basic Reproduction Number | 1 | 2020 | 2676 | 0.02 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2021 | 3444 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3633 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.02 | Why? |
| Point-of-Care Systems | 1 | 2021 | 2955 | 0.02 | Why? |
| State Medicine | 1 | 2020 | 2847 | 0.02 | Why? |
| Attitude to Health | 1 | 2020 | 2002 | 0.02 | Why? |
| Neutralization Tests | 1 | 2020 | 6698 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2016 | 3395 | 0.02 | Why? |
| Pregnancy Complications, Infectious | 1 | 2012 | 11559 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| New York City | 1 | 2020 | 7432 | 0.02 | Why? |
| Parents | 1 | 2020 | 2758 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2021 | 6740 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2021 | 8248 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.01 | Why? |
| Phylogeny | 1 | 2021 | 13341 | 0.01 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.01 | Why? |
| Health Behavior | 1 | 2020 | 4449 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Lung | 2 | 2020 | 31049 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.01 | Why? |
| Triage | 1 | 2020 | 7151 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Registries | 1 | 2018 | 12327 | 0.01 | Why? |
| Italy | 1 | 2021 | 38444 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Pregnancy | 1 | 2012 | 23879 | 0.01 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |